This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Rasagiline in the Treatment of Persistent Negative Symptoms of Schizophrenia

This study has been completed.
Sponsor:
Collaborator:
Stanley Medical Research Institute
Information provided by (Responsible Party):
Robert W. Buchanan, M.D., University of Maryland
ClinicalTrials.gov Identifier:
NCT00492336
First received: June 26, 2007
Last updated: June 17, 2013
Last verified: June 2013
Results First Received: February 1, 2013  
Study Type: Interventional
Study Design: Allocation: Randomized;   Intervention Model: Parallel Assignment;   Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor);   Primary Purpose: Treatment
Condition: Schizophrenia
Interventions: Drug: rasagiline (Pharmacodynamics)
Drug: Placebo

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
Subjects were recruited between May 2007-October 2011 from mental health clinics throughout the community.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
Participants were excluded before assignment to treatment groups if they met any of the exclusion criteria, if they became clinically unstable, or they decided that the demands of the study were too great. 84 participants were enrolled into active participation; 57 started study treatment.

Reporting Groups
  Description
Rasagiline Treatment with Rasagiline
Inactive Pill Treatment with Placebo

Participant Flow:   Overall Study
    Rasagiline   Inactive Pill
STARTED   28   29 
COMPLETED   26   23 
NOT COMPLETED   2   6 



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
Rasagiline Treatment with Rasagiline
Inactive Pill Treatment with Placebo
Total Total of all reporting groups

Baseline Measures
   Rasagiline   Inactive Pill   Total 
Overall Participants Analyzed 
[Units: Participants]
 28   29   57 
Age 
[Units: Participants]
     
<=18 years   0   0   0 
Between 18 and 65 years   28   29   57 
>=65 years   0   0   0 
Age 
[Units: Years]
Mean (Standard Deviation)
 46.3  (12.2)   45.9  (11.1)   46.09  (11.59) 
Gender 
[Units: Participants]
     
Female   4   7   11 
Male   24   22   46 
Region of Enrollment 
[Units: Participants]
     
United States   28   29   57 


  Outcome Measures

1.  Primary:   Scale for the Assessment of Negative Symptoms (SANS)   [ Time Frame: Every 4 weeks over a 12 week period ]

2.  Secondary:   Neuropsychological Tests, Including RBANS, Probabilistic Learning Task, and N-Back Task   [ Time Frame: Beginning of treatment phase (week 0) and end of treatment phase (week 12) ]
Results not yet reported.   Anticipated Reporting Date:   No text entered.  

3.  Secondary:   Simpson Angus Scale   [ Time Frame: Every 4 weeks ]
Results not yet reported.   Anticipated Reporting Date:   No text entered.  

4.  Secondary:   Side Effect Checklist and Vital Signs   [ Time Frame: Weekly ]
Results not yet reported.   Anticipated Reporting Date:   No text entered.  


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information
  Hide More Information

Certain Agreements:  
All Principal Investigators ARE employed by the organization sponsoring the study.


Results Point of Contact:  
Name/Title: Dr. Robert Buchanan, M.D.
Organization: Maryland Psychiatric Research Center
phone: 410-402-7876
e-mail: rwbuchanan@mprc.umaryland.edu


Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Responsible Party: Robert W. Buchanan, M.D., University of Maryland
ClinicalTrials.gov Identifier: NCT00492336     History of Changes
Other Study ID Numbers: HP-00043807
H-27877 ( Other Identifier: University of Maryland Baltimore )
Study First Received: June 26, 2007
Results First Received: February 1, 2013
Last Updated: June 17, 2013